NASDAQ:CTRX - Catamaran Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$61.47
Today's RangeN/A
52-Week Range$39.40 - $61.50
VolumeN/A
Average Volume2.83 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Catamaran Corporation (Catamaran) is a provider of pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefit management industry. The Company operates in two segments: PBM and HCIT. The Company offers PBM services, which are marketed under the Catamaran PBM brand, and is engaged in owning and operating a network of mail and specialty pharmacies. In addition, the Company is a national provider of drug benefits to its customers under the federal government's Medicare Part D program. The Company's HCIT product offerings include a range of software products for managing prescription drug programs and for drug prescribing and dispensing. The Company's customers include organizations in the pharmaceutical supply chain, such as pharmacy benefit managers, managed care organizations, self-insured employer groups, unions, third-party healthcare plan administrators, and state and federal government entities.

Receive CTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Services
SectorN/A
Current SymbolNASDAQ:CTRX
Previous SymbolNASDAQ:SXCI
CUSIP14888710
Phone+1-800-2823232

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
OptionableNot Optionable

Catamaran (NASDAQ:CTRX) Frequently Asked Questions

What is Catamaran's stock symbol?

Catamaran trades on the NASDAQ under the ticker symbol "CTRX."

How were Catamaran's earnings last quarter?

Catamaran Corp (NASDAQ:CTRX) posted its earnings results on Thursday, February, 26th. The healthcare company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.61 by $0.06. The healthcare company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.57 billion. The company's revenue for the quarter was up 26.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.56 earnings per share. View Catamaran's Earnings History.

Has Catamaran been receiving favorable news coverage?

Media stories about CTRX stock have trended somewhat positive on Tuesday, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Catamaran earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned media coverage about the healthcare company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Catamaran?

Shares of CTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catamaran's official website?

The official website for Catamaran is http://www.catamaranrx.com/.

How can I contact Catamaran?

Catamaran's mailing address is 1600 McConnor Pkwy, SCHAUMBURG, IL 60173-6801, United States. The healthcare company can be reached via phone at +1-800-2823232.


MarketBeat Community Rating for Catamaran (NASDAQ CTRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  417
MarketBeat's community ratings are surveys of what our community members think about Catamaran and other stocks. Vote "Outperform" if you believe CTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel